FDA Authorizes Updated Protein-Based COVID-19 Vaccine From Novavax For Fall Booster Campaign

Novavax's protein-based COVID-19 vaccine has been authorized by the FDA for use in people aged 12 and up.
The vaccine provides protection against current dominant Omicron subvariants like BQ.1.1.
Novavax's vaccine uses a more traditional protein-based approach compared to mRNA vaccines from Pfizer and Moderna.
The CDC recommends COVID-19 vaccine booster shots for most Americans heading into the fall and winter.
The Novavax vaccine provides another option alongside mRNA vaccines for the fall booster campaign.